Physician profile
Kerri Anne Steele
NPI 1366574857
$164,088.47
in general payments reported to CMS, 2019-2025
14 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $15K · 2022: $18K · 2023: $19K · 2024: $18K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $68K · Royalty Or License: $37K · Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $68,006.47 |
| Royalty Or License | $36,729.00 |
| Food and Beverage | $459.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pediatric Alliance LLC | $163,403.47 | 2019-2025 | |
| Seqirus USA INC | $128.15 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Sanofi Pasteur INC. | $113.25 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $104.33 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $53.07 | 2024 | |
| Sanofi-Aventis U.S. LLC | $45.72 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $41.55 | 2025 | Jornay Pm |
| Pfizer INC. | $36.30 | 2022-2024 | |
| Alk-Abello, INC | $35.90 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $35.79 | 2021-2023 | Qelbree |
| Sobi, INC | $30.59 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.63 | 2022 | |
| Corium, LLC | $20.64 | 2022 | |
| Phadia US INC. | $15.08 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$275,579.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.